



EULAR 2024 CORPORATE MEMBERS ATTRIBUTION PROCESS

1. Introduction

For the EULAR 2024 European Congress of Rheumatology (EULAR 2024), attribution of exhibiting space, satellite symposia slots and other items open for investment, will be handled according to a points system which will be calculated as follows:

2. Total of points per company used as basis for EULAR 2024 ranking

- Corporate Members will be awarded 10 points for each year the company has exhibited and/or organised a satellite symposium and other items open for investment at EULAR (no maximum points)
- 1 point per Euro 2'500 invoiced and paid (excl. VAT) will be awarded to Corporate Members for booking of exhibiting space, satellite symposia and other items open for investment since the EULAR 2021 broken down as follows:
 - o 100% of total investment for the EULAR 2023 (i.e. Euro 10'000 = 4 points)
 - o 50% of total investment for EULAR 2022 (i.e. Euro 10'000 = 2 points)
 - o 25% of total investment for EULAR 2021 (i.e. Euro 10'000 = 1 point)
- Corporate Members are also awarded 1 point for each delegate registration made for the EULAR 2023 (50% of the points for registration at the EULAR 2022 and 25% of the points for registration at the EULAR 2021).

3. Points attribution as from EULAR 2024

- Corporate Members will be awarded 10 points for each year the company has exhibited and/or organised a satellite symposium and other items open for investment at EULAR (no maximum points)
- 1 point per Euro 2'500 invoiced and paid (excl. VAT) will be awarded to Corporate Members for booking of exhibition space, satellite symposia and other items open for investment
- Corporate Members will also be awarded 1 point for each delegate virtual registration (if any) and 3 points for each delegate onsite registration made for the EULAR 2024. To have points credited to your company for delegate registrations, please ensure that any agency, subsidiary, and intermediary registering delegates on behalf of your company, inform the registration department accordingly
- The total points attributed for the following congress is based on the investment and delegate registrations of the 3 previous years (100% for EULAR 2024, 50% for EULAR 2023 and 25% for EULAR 2022).

In case of a merger between companies, the highest number of points between the two companies will be used for the following event, if notice in writing is received by the EULAR Office before 31 October of the year preceding the congress.



4. Outstanding amounts due on EULAR 2023 European Congress of Rheumatology (EULAR 2023)

In case of outstanding amounts by 1st September 2023, the points corresponding to the items not yet paid will be deducted from the EULAR 2024 ranking.

5. Attribution of Exhibition Space, Satellite Symposia and other items for investment

Exhibition Space, Satellite Symposia and other items for investment will be attributed according to the overall EULAR 2024 ranking, i.e. 1st company enjoys 1st choice of exhibition space, satellite symposium and other items for investment, 2nd company enjoys 2nd choice, etc.

Should a company request more than one exhibition space, satellite symposium or other items for investment, it will be necessary to indicate priority, i.e. 1st exhibition space, satellite symposium and other items for investment, 2nd, 3rd, etc.

6. Ranking Overview EULAR 2024 (based on 2021-2023)

Ranking	Company	TOTAL POINTS
1	AbbVie Inc.	4'359
2	UCB BioPharma SRL	3'378
3	Pfizer Inc.	2'949
4	Janssen Pharmaceutica NV	2'896
5	Novartis Pharma AG	1'915
6	Eli Lilly and Company	1'637
7	AstraZeneca UK Ltd.	1'414
8	GlaxoSmithKline Research and Development Ltd.	1'245
9	Bristol-Myers Squibb	1'220
10	Galapagos NV	1'194
11	medac GmbH	1'175
12	Boehringer Ingelheim International GmbH	924
13	Amgen (Europe) GmbH	888
14	F. Hoffmann-La Roche Ltd.	552
15	Vifor Fresenius Medical Care Renal Pharma Ltd.	537
16	IBSA Institut Biochimique SA	513
17	Fresenius Kabi SwissBioSim	494
18	Celltrion Healthcare Co. Ltd.	415
19	Otsuka Pharmaceutical Europe Ltd.	120
20	Biogen International GmbH	115
21	Merck Healthcare KGaA	78
22	Gilead Sciences Europe Ltd.	47

EULAR Office
 Kilchberg, August 2023